Cargando…

Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected billions of individuals and is the cause of the current global coronavirus disease 2019 (COVID-19) pandemic. We previously developed an mRNA vaccine (LVRNA009) based on the S protein of the Wuhan-Hu-1 strain; the phases I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jianglong, Liu, Qi, Liu, Jun, Fang, Zihui, Luo, Liping, Li, Shuang, Lei, Yixin, Li, Zhi, Jin, Jing, Xie, Ronglin, Peng, Yucai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693459/ https://www.ncbi.nlm.nih.gov/pubmed/36366316 http://dx.doi.org/10.3390/vaccines10111807

Ejemplares similares

An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs
por: Li, Jianglong, et al.
Publicado: (2022)

SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
por: Ma, Qinhai, et al.
Publicado: (2023)

Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern
por: Kumari, Monika, et al.
Publicado: (2023)

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
por: Corleis, Björn, et al.
Publicado: (2023)

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
por: Scheaffer, Suzanne M., et al.
Publicado: (2022)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

Bivalent mRNA vaccine-elicited SARS-CoV-2 specific T cells recognise the omicron XBB sublineage
por: Traut, Caroline C, et al.
Publicado: (2023)

Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine
por: Tauzin, Alexandra, et al.
Publicado: (2023)

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants
por: Li, Yaning, et al.
Publicado: (2022)

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
por: Huiberts, Anne J, et al.
Publicado: (2023)

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants
por: Wang, Rui, et al.
Publicado: (2022)

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
por: Yuan, Yaochang, et al.
Publicado: (2022)

Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis
por: Huth, Luca, et al.
Publicado: (2023)

Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants
por: Wang, Rui, et al.
Publicado: (2022)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

Myocarditis With Ventricular Tachycardia Following Bivalent COVID-19 mRNA Vaccination
por: Yamamoto, Jumpei, et al.
Publicado: (2023)

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
por: Lasrado, Ninaad, et al.
Publicado: (2023)

Clinical Characteristics of Omicron SARS-CoV-2 Variant Infection After Non-mRNA-Based Vaccination in China
por: Zeng, Qing-Lei, et al.
Publicado: (2022)

A bivalent subunit vaccine efficiently produced in Pichia pastoris against SARS-CoV-2 and emerging variants
por: Xu, Huifang, et al.
Publicado: (2023)

Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates
por: Wu, Yixin, et al.
Publicado: (2022)

Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
por: Liu, Cong, et al.
Publicado: (2022)

Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines
por: Ye, Zi-Wei, et al.
Publicado: (2022)

RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
por: Liang, Qingtai, et al.
Publicado: (2022)

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
por: Hannawi, Suad, et al.
Publicado: (2023)

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants
por: Fan, Na, et al.
Publicado: (2022)

Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023
por: Kim, Ryu Kyung, et al.
Publicado: (2023)

mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern
por: Wang, Haomeng, et al.
Publicado: (2022)

2353. SARS-CoV-2 Variants among US Veterans after COVID-19 Bivalent Vaccine Administration
por: Holodniy, Mark, et al.
Publicado: (2023)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
por: Link-Gelles, Ruth, et al.
Publicado: (2022)

Ph-Positive B-Cell Acute Lymphoblastic Leukemia Occurring after Receipt of Bivalent SARS-CoV-2 mRNA Vaccine Booster: A Case Report
por: Ang, Shy-Yau, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency
por: Li, Maochen, et al.
Publicado: (2021)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
por: Li, Gen, et al.
Publicado: (2022)

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
por: Choi, Angela, et al.
Publicado: (2021)

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lkfem1s4elpd6ikaqnhn6173nc